I love this. I just graduated at the age of 60 with a masters in patient safety and healthcare quality precisely because I knew that despite the existence of effective interventions, most eligible patients weren’t receiving them. That’s where implementation science comes in. Assuming the patient has access to the “miracle drug”, the drug isn’t miraculous if patients don’t take it. That’s where implementation science comes in. Hopefully there will be more good science to inform how best to ensure every patient who can benefit from an intervention receives it.
Much as I hate combination medicines has there been any discussion about an ARB/SGLT2 polypill? Dr. Valentin Fuster from Mt. Sinai has been beating this drum in the cardiovascular space for many years but I'm not sure how far he's gotten with it. Last time I looked, I think dapagliflozin is close to losing patent protection. Thanks for listening. David Lavimoniere PharmD Field Medical Director, Calliditas Therapeutics.
It’s OK. It’s OK you can start the medicine yourself. You can deal with the prior authorization. You can deal with the yeast infections. And urinary tract infections. It doesn’t have to fall on me if you want it you can do it. You’re a doctor also. I don’t have to be at the bottom of the hill. You can be there with me. You’re probably making more than me so it’s probably appropriate that you’re down here with me.
I would add GLP-1s to the list of agents shown to reduce progression to ESRD in patients with diabetes and obesity. Obviously, GLP-1s come with a hefty price tag. When RASAs and SGLT-2 inhibitors are underutilized, a scenario where GLP-1s are preferentially utilized, is not unimaginable
Most of us don’t get to practice or get care at a Kaiser, a Sentra or an Intermountain. In an era of fragmented EHRs, an integrated system is our best bet at driving up adoption of these life (and kidney) saving meds
Brother I hear you loud and clear. However, while ACE/ARB's widely available cheap. Sodium-glucose cotransporter-2 inhibitor (SGLT2i) not so much even though FDA has approved them to be manufactured. At least not that I have seen.
Typical Pharm industry greed. The whole industry is counting on Atheism and no repercussions in the next life, as it is obvious they have no shame in this one.
Cheapest I can find is over $500 without having to fill out bullshit begging for cheaper drugs to get in the pharm program to get for lower price that is still quite steep
I would like you to remind that the intervention was in Denmark, where govermental insurance covers most of the cost of the drug. Here in Estonia, SGLT2i cost 10 euros a month maximum.
I love this. I just graduated at the age of 60 with a masters in patient safety and healthcare quality precisely because I knew that despite the existence of effective interventions, most eligible patients weren’t receiving them. That’s where implementation science comes in. Assuming the patient has access to the “miracle drug”, the drug isn’t miraculous if patients don’t take it. That’s where implementation science comes in. Hopefully there will be more good science to inform how best to ensure every patient who can benefit from an intervention receives it.
Much as I hate combination medicines has there been any discussion about an ARB/SGLT2 polypill? Dr. Valentin Fuster from Mt. Sinai has been beating this drum in the cardiovascular space for many years but I'm not sure how far he's gotten with it. Last time I looked, I think dapagliflozin is close to losing patent protection. Thanks for listening. David Lavimoniere PharmD Field Medical Director, Calliditas Therapeutics.
It’s OK. It’s OK you can start the medicine yourself. You can deal with the prior authorization. You can deal with the yeast infections. And urinary tract infections. It doesn’t have to fall on me if you want it you can do it. You’re a doctor also. I don’t have to be at the bottom of the hill. You can be there with me. You’re probably making more than me so it’s probably appropriate that you’re down here with me.
I would add GLP-1s to the list of agents shown to reduce progression to ESRD in patients with diabetes and obesity. Obviously, GLP-1s come with a hefty price tag. When RASAs and SGLT-2 inhibitors are underutilized, a scenario where GLP-1s are preferentially utilized, is not unimaginable
Most of us don’t get to practice or get care at a Kaiser, a Sentra or an Intermountain. In an era of fragmented EHRs, an integrated system is our best bet at driving up adoption of these life (and kidney) saving meds
Brother I hear you loud and clear. However, while ACE/ARB's widely available cheap. Sodium-glucose cotransporter-2 inhibitor (SGLT2i) not so much even though FDA has approved them to be manufactured. At least not that I have seen.
Typical Pharm industry greed. The whole industry is counting on Atheism and no repercussions in the next life, as it is obvious they have no shame in this one.
Cheapest I can find is over $500 without having to fill out bullshit begging for cheaper drugs to get in the pharm program to get for lower price that is still quite steep
I would like you to remind that the intervention was in Denmark, where govermental insurance covers most of the cost of the drug. Here in Estonia, SGLT2i cost 10 euros a month maximum.